UPCC 46420: Phase I Open Label Multicenter Dose Escalation Study of YTB323 in Adult Patients with CLL/SLL and DLBCL

Age
18 years - 99 years
Gender
All
Location
1

Brief description of study

Please refer to Section 2 of the full protocol (Objectives and endpoints) Please refer to Section 2 of the full protocol (Objectives and endpoints) Please refer to Section 2 of the full protocol (Objectives and endpoints)

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 18 years - 99 years
  • Gender: All
Updated on 04 Aug 2024. Study ID: 844671
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Office of Clinical Research